Abstract
Purpose: To investigate the clinical application of a stereotactic body radiation therapy (SBRT) boost in locally advanced pancreatic cancer patients with a focus on local efficacy and toxicity. Methods and Materials: We retrospectively reviewed 30 patients with locally advanced and nonmetastatic pancreatic cancer who had been treated between 2004 and 2006. Follow-up duration ranged from 4 to 41 months (median, 14.5 months). A total dose of 40 Gy was delivered in 20 fractions using a conventional three-field technique, and then a single fraction of 14, 15, 16, or 17 Gy SBRT was administered as a boost without a break. Twenty-one patients received chemotherapy. Overall and local progression-free survival were calculated and prognostic factors were evaluated. Results: One-year overall survival and local progression-free survival rates were 60.0% and 70.2%, respectively. One patient (3%) developed Grade 4 toxicity. Carbohydrate antigen 19-9 response was found to be an independent prognostic factor for survival. Conclusions: Our findings indicate that a SBRT boost provides a safe means of increasing radiation dose. Based on the results of this study, we recommend that a well controlled Phase II study be conducted on locally advanced pancreatic cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1456-1461 |
| Number of pages | 6 |
| Journal | International Journal of Radiation Oncology Biology Physics |
| Volume | 75 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2009 Dec 1 |
| Externally published | Yes |
Fingerprint
Keywords
- CyberKnife
- Pancreatic cancer
- Radiation therapy
- Stereotactic
ASJC Scopus subject areas
- Radiation
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Cite this
Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer. / Seo, Young Seok; Kim, Mi Sook; Yoo, Sung Yul; Cho, Chul Koo; Yang, Kwang Mo; Yoo, Hyung Jun; Choi, Chul Won; Lee, Dong Han; Kim, Jin; Kim, Min Suk; Kang, Hye Jin; Kim, Young Han.
In: International Journal of Radiation Oncology Biology Physics, Vol. 75, No. 5, 01.12.2009, p. 1456-1461.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stereotactic Body Radiation Therapy Boost in Locally Advanced Pancreatic Cancer
AU - Seo, Young Seok
AU - Kim, Mi Sook
AU - Yoo, Sung Yul
AU - Cho, Chul Koo
AU - Yang, Kwang Mo
AU - Yoo, Hyung Jun
AU - Choi, Chul Won
AU - Lee, Dong Han
AU - Kim, Jin
AU - Kim, Min Suk
AU - Kang, Hye Jin
AU - Kim, Young Han
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Purpose: To investigate the clinical application of a stereotactic body radiation therapy (SBRT) boost in locally advanced pancreatic cancer patients with a focus on local efficacy and toxicity. Methods and Materials: We retrospectively reviewed 30 patients with locally advanced and nonmetastatic pancreatic cancer who had been treated between 2004 and 2006. Follow-up duration ranged from 4 to 41 months (median, 14.5 months). A total dose of 40 Gy was delivered in 20 fractions using a conventional three-field technique, and then a single fraction of 14, 15, 16, or 17 Gy SBRT was administered as a boost without a break. Twenty-one patients received chemotherapy. Overall and local progression-free survival were calculated and prognostic factors were evaluated. Results: One-year overall survival and local progression-free survival rates were 60.0% and 70.2%, respectively. One patient (3%) developed Grade 4 toxicity. Carbohydrate antigen 19-9 response was found to be an independent prognostic factor for survival. Conclusions: Our findings indicate that a SBRT boost provides a safe means of increasing radiation dose. Based on the results of this study, we recommend that a well controlled Phase II study be conducted on locally advanced pancreatic cancer.
AB - Purpose: To investigate the clinical application of a stereotactic body radiation therapy (SBRT) boost in locally advanced pancreatic cancer patients with a focus on local efficacy and toxicity. Methods and Materials: We retrospectively reviewed 30 patients with locally advanced and nonmetastatic pancreatic cancer who had been treated between 2004 and 2006. Follow-up duration ranged from 4 to 41 months (median, 14.5 months). A total dose of 40 Gy was delivered in 20 fractions using a conventional three-field technique, and then a single fraction of 14, 15, 16, or 17 Gy SBRT was administered as a boost without a break. Twenty-one patients received chemotherapy. Overall and local progression-free survival were calculated and prognostic factors were evaluated. Results: One-year overall survival and local progression-free survival rates were 60.0% and 70.2%, respectively. One patient (3%) developed Grade 4 toxicity. Carbohydrate antigen 19-9 response was found to be an independent prognostic factor for survival. Conclusions: Our findings indicate that a SBRT boost provides a safe means of increasing radiation dose. Based on the results of this study, we recommend that a well controlled Phase II study be conducted on locally advanced pancreatic cancer.
KW - CyberKnife
KW - Pancreatic cancer
KW - Radiation therapy
KW - Stereotactic
UR - http://www.scopus.com/inward/record.url?scp=71649106367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71649106367&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2009.01.042
DO - 10.1016/j.ijrobp.2009.01.042
M3 - Article
C2 - 19783379
AN - SCOPUS:71649106367
VL - 75
SP - 1456
EP - 1461
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
SN - 0360-3016
IS - 5
ER -